inpefa：INPEFATM (sotagliflozin) tablets
INPEFATM (sotagliflozin) tablets
INPEFAisnotindicatedforglycemiccontrol.Type2diabetesmellitusandpancreaticdisorders(e.g.,historyofpancreatitisorpancreaticsurgery)arealso ...。其他文章還包含有：「FDAApprovesInpefafortheTreatmentofHeartFailure」、「highlightsofprescribinginformation」、「INPEFAcancauseserioussideeffects」、「InpefaOral:Uses,SideEffects,Interactions」、「Inpefa:Uses,Dosage」、「NowApproved」、「Once」、「Sotagli...
查看更多 離開網站
FDA Approves Inpefa for the Treatment of Heart Failure
https://www.empr.com
The Food and Administration (FDA) has approved Inpefa™ (sotagliflozin) to reduce the risk of cardiovascular (CV) death, hospitalization for ...
highlights of prescribing information
https://dailymed.nlm.nih.gov
INPEFA is a prescription medicine used to reduce the risk of death due to heart problems (cardiovascular death), hospitalization for heart failure, and urgent ...
INPEFA can cause serious side effects
https://dailymed.nlm.nih.gov
INPEFA is a prescription medicine used to reduce the risk of death due to heart problems (cardiovascular death), hospitalization for heart failure, and urgent ...
Inpefa Oral: Uses, Side Effects, Interactions
https://www.webmd.com
Sotagliflozin is used by people with heart failure or by people with type 2 diabetes, kidney disease, and other heart disease risk factors to lower the risk ...
Inpefa: Uses, Dosage
https://www.drugs.com
Inpefa is an oral, once-daily tablet that contains sotagliflozin which may be used to reduce the risk of cardiovascular death, ...
Now Approved
https://www.inpefahcp.com
INPEFA™ is an inhibitor of SGLT2 and SGLT1 for patients with heart failure or patients with comorbidities and other cardiovascular risk factors.
Once
https://www.uspharmacist.com
On May 26, 2023, Lexicon Pharmaceuticals, Inc., announced the FDA approval of Inpefa (sotagliflozin), a once-daily oral tablet to decrease ...
Sotagliflozin for the Treatment of Heart Failure
https://www.clinicaltrialsaren
INPEFA™ (sotagliflozin) is a once-daily oral tablet indicated to reduce the risk of cardiovascular death, hospitalisation for heart failure ...